Rapid Prototyping and Deployment of a Therapeutic Pan-Coronavirus Fusogenix DNA Vaccine Engineered to Eliminate ADE
- Funded by Canadian Institutes of Health Research (CIHR), Research Nova Scotia
- Total publications:1 publications
Grant number: 172710
Grant search
Key facts
Disease
COVID-19Start & end year
20202020Known Financial Commitments (USD)
$3,131,250Funder
Canadian Institutes of Health Research (CIHR), Research Nova ScotiaPrincipal Investigator
PendingResearch Location
CanadaLead Research Institution
University of Alberta Experimental OncologyResearch Priority Alignment
N/A
Research Category
Vaccines research, development and implementation
Research Subcategory
Pre-clinical studies
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
In this project, this team will rapidly develop, validate and clinically evaluate a novel DNA Vaccine against COVID-19 utilizing well-validated Fusogenix proteolipid vehicle (PLV) intracellular delivery platform. The use of a plasmid DNA vaccine will allow us to utilize multiple epitopes from key immunogenic SARS-COV-2 proteins, generating protection against structural components of the novel coronavirus, which should not only protect against viral entry but provide a robust cell-based response during active infection. Working with an international multi-disciplinary team including investigators at University of Alberta, Dalhousie University, Entos Pharmaceuticals, VIDO, EpiVax, Virscio and a pharmaceutical partner, we will rapidly prototype, validate and clinically evaluate a pan-coronavirus DNA vaccine. Clinical trials will be initiated at the Canadian center for Vaccinology in Halifax within 8 weeks of project initiation, with the goal of a commercial release within one year.
Publicationslinked via Europe PMC
Last Updated:16 hours ago
View all publications at Europe PMC